Cytochrome P450
CYPs

Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism.
## Cytochrome P450 Inhibitors & Modulators

### (+)-Ketoconazole

**Cat. No.: HY-B0105A**

**Bioactivity:** (+)-Ketoconazole is an imidazole anti-fungal agent, a CYP3A4 inhibitor. Target: CYP3A4 (+)-Ketoconazole, an imidazole anti-fungal agent, has often produced features of androgen deficiency including decreased libido, gynecomastia, impotence, oligospermia, and decreased testosterone levels, in...

**Purity:** 99.51%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

### (-)-Cephaeline dihydrochloride

**Cat. No.: HY-N2260**

**Bioactivity:** (-)-Cephaeline dihydrochloride is an enantiomer of Cephaeline dihydrochloride. Cephaeline dihydrochloride is a selective CYP2D6 inhibitor with IC<sub>50</sub> of 121 μM.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 2 mg, 5 mg

### 1-Aminobenzotriazole

**Cat. No.: HY-103389**

**Bioactivity:** 1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of cytochrome P450 (P450).

**Purity:** 99.88%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in Water, 50 mg, 100 mg, 200 mg, 500 mg

### 1-Ethynynaphthalene

**Cat. No.: HY-111430**

**Bioactivity:** 1-Ethynynaphthalene is a selective inhibitor of cytochrome P450 1B1.

**Purity:** 99.27%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

### 4'-Methylchrysoeriol

**Cat. No.: HY-112734**

**Bioactivity:** 4'-Methylchrysoeriol is a potent inhibitor of Cytochrome P450 enzymes, with an IC<sub>50</sub> of 19 nM for human P450 1B1-dependent EROD.

**Purity:** 99.17%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Abiraterone

**Cat. No.: HY-70013**

**Bioactivity:** Abiraterone is a potent, selective, and irreversible CYP17 inhibitor with IC<sub>50</sub> of 2 to 4 nM.

**Purity:** 99.61%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMF, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g

### Abiraterone acetate

**Cat. No.: HY-75054**

**Bioactivity:** Abiraterone acetate is an oral, potent, selective, and irreversible inhibitor of CYP17.

**Purity:** 99.92%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g, 5 g

### Antihistamine-1

**Cat. No.: HY-100238**

**Bioactivity:** Antihistamine-1 is a H1-antihistamine (K<sub>i</sub> = 6.9 nM) with acceptable blood-brain barrier penetration and also an inhibitor of CYP2D6 and hERG channel with IC<sub>50</sub> of 5.4 and 0.8 μM, respectively.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

### Apigenin

**Cat. No.: HY-N1201**

**Bioactivity:** Apigenin is a competitive CYP2C9 inhibitor with a K<sub>i</sub> of 2 μM.

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

### Bergamottin

**Cat. No.: HY-N2194**

**Bioactivity:** Bergamottin is a potent and competitive CYP1A1 inhibitor with a K<sub>i</sub> of 10.703 nM.

**Purity:** 99.57%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 25 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bergapten (5-Methoxypsoralen)</td>
<td>HY-N0370</td>
<td>Bergapten is a natural anti-inflammatory and anti-tumor agent isolated from bergamot essential oil, other citrus essential oils and grapefruit juice. Bergapten is inhibitory towards mouse and human CYP isoforms.</td>
<td>99.92%</td>
<td>Phase 3</td>
<td>10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>Bergaptol (5-Hydroxypsoralen; 4-Hydroxybergapten)</td>
<td>HY-76316</td>
<td>Bergaptol A hydroxylated psoralen that acts as a potent inhibitors of debenzylation activity of CYP3A4 enzyme with an IC50 value of 24.92 μM. Recent studies suggest that it may have antiproliferative and anticancer properties. Target: CYP3A4.</td>
<td>99.28%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 500 mg</td>
</tr>
<tr>
<td>BI 689648</td>
<td>HY-101217</td>
<td>BI 689648 is a novel, highly selective aldosterone synthase inhibitor which can inhibit CYP11B1 and CYP11B2 with IC50s of 310 and 2.1 nM, respectively.</td>
<td>99.20%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg</td>
</tr>
<tr>
<td>BMS-819881</td>
<td>HY-12433</td>
<td>BMS-819881 is a melaninconcentrating hormone receptor 1 (MCHR1) antagonist, which binds rat MCHR1 with a K_i of 7 nM. BMS-819881 also is selective and potent for CYP3A4 activity with an EC_{50} of 13 μM.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>BVT948</td>
<td>HY-100625</td>
<td>BVT948 is a protein tyrosine phosphatase (PTP) inhibitor which can also inhibit several cytochrome P450 (P450) isoforms and lysine methyltransferase SETDB8.</td>
<td>99.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg</td>
</tr>
<tr>
<td>Carbosulfan</td>
<td>HY-B2015</td>
<td>Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.</td>
<td>98.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td>CDD3505</td>
<td>HY-100901</td>
<td>CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.</td>
<td>95.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>CDD3506</td>
<td>HY-100902</td>
<td>CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Cecropin B</td>
<td>HY-P0092</td>
<td>Cecropin B has high level of antimicrobial activity and is considered as a valuable peptide antibiotic.</td>
<td>98.12%</td>
<td>No Development Reported</td>
<td>500µg, 1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>Chlorzoxazone</td>
<td>HY-B1462</td>
<td>Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It acts on the spinal cord by depressing reflexes. Chlorzoxazone is currently being used as a marker substrate in vitro/vivo studies to quantify cytochrome P450 2E1 (CYP2E1) activity in...</td>
<td>99.72%</td>
<td>Released</td>
<td>10mM x 1mL in DMSO, 5 g</td>
</tr>
</tbody>
</table>
| **Choline Fenofibrate**  
| **(ABT-335)** | **Cat. No.: HY-14739** |
| **Bioactivity:** | Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. |
| **Purity:** | 99.81% |
| **Clinical Data:** | Launched |
| **Size:** | 10mM x 1mL in DMSO, 10 mg, 100 mg |

| **Clarithromycin** | **Cat. No.: HY-17508** |
| **Bioactivity:** | Clarithromycin is a macroline antibiotic and a CYP3A4 inhibitor. Target: Antibacterial; CYP3A4 Clarithromycin is a macroline antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias). |
| **Purity:** | 98.0% |
| **Clinical Data:** | Launched |
| **Size:** | 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg |

| **Cobicistat**  
| **(GS-9350)** | **Cat. No.: HY-10493** |
| **Bioactivity:** | Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) enzymes with IC<sub>50</sub> of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications. |
| **Purity:** | 98.0% |
| **Clinical Data:** | Launched |
| **Size:** | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **D4-abiraterone**  
| **(Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite)** | **Cat. No.: HY-109619** |
| **Bioactivity:** | D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3BHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor. |
| **Purity:** | 99.42% |
| **Clinical Data:** | No Development Reported |
| **Size:** | 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg |

| **Dafadine-A** | **Cat. No.: HY-16670** |
| **Bioactivity:** | Dafadine-A, an analog of dafadine, is a novel inhibitor of DAF-9 cytochrome P450 in the nematode Caenorhabditis elegans; also inhibits the mammalian ortholog of DAF-9(CYP27A1). |
| **Purity:** | 98.77% |
| **Clinical Data:** | No Development Reported |
| **Size:** | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg |

| **Dihydromethysticin**  
| **(+)-Dihydromethysticin)** | **Cat. No.: HY-N0921** |
| **Bioactivity:** | Dihydromethysticin is one of the six major kavalactones found in the kava plant; has marked activity on the induction of CYP3A23. |
| **Purity:** | >98% |
| **Clinical Data:** | No Development Reported |
| **Size:** | 5 mg, 10 mg |

| **Diosmetin** | **Cat. No.: HY-N0125** |
| **Bioactivity:** | Diosmetin is a natural flavonoid which inhibits human CYP1A enzyme activity with an IC<sub>50</sub> of 40 μM in HepG2 cell. |
| **Purity:** | 99.45% |
| **Clinical Data:** | No Development Reported |
| **Size:** | 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg |

| **DMU2105** | **Cat. No.: HY-101284** |
| **Bioactivity:** | DMU2105 is a potent and specific CYP1B1 inhibitor, with IC<sub>50</sub> of 10 nM and 742 nM for CYP1B1 and CYP1A1, respectively. |
| **Purity:** | 98.12% |
| **Clinical Data:** | No Development Reported |
| **Size:** | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **DMU2139** | **Cat. No.: HY-101285** |
| **Bioactivity:** | DMU2139 is a potent and specific CYP1B1 inhibitor, with IC<sub>50</sub> of 9 nM and 795 nM for CYP1B1 and CYP1A1, respectively. |
| **Purity:** | 98.0% |
| **Clinical Data:** | No Development Reported |
| **Size:** | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **Fenofibrate** | **Cat. No.: HY-17356** |
| **Bioactivity:** | Fenofibrate is a PPAR<sub>α</sub> agonist with an EC<sub>50</sub> of 30 μM. |
| **Purity:** | 99.92% |
| **Clinical Data:** | Launched |
| **Size:** | 10mM x 1mL in DMSO, 5 g, 10 g |
**Furafylline**  
Cat. No.: HY-107204

**Bioactivity:** Furafylline is a potent and selective inhibitor of human cytochrome P450IA2 with an IC\textsubscript{50} of 0.07 μM.

**Purity:** 99.86%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 1 mg

---

**Galangin**  
(Norizalpinin; 3,5,7-Trihydroxyflavone)  
Cat. No.: HY-N0382

**Bioactivity:** Galangin is an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of CYP1A2 activity.

**Purity:** 99.96%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg

---

**Galeterone**  
(TOK-001; VN-124-1)  
Cat. No.: HY-70006

**Bioactivity:** Galeterone (TOK-001) is a multifunctional antiandrogen and CYP17 inhibitor (IC\textsubscript{50}=47 nM) in castration resistant prostate cancer (CRPC).

**Purity:** 99.85%  
**Clinical Data:** Phase 3  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

---

**Gemfibrozil**  
(CI-719)  
Cat. No.: HY-B0258

**Bioactivity:** Gemfibrozil is an activator of PPAR-\(\alpha\), used as a lipid-lowering drug. Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with \(K_i\) values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

**Purity:** 99.91%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

---

**Gentiopicroside**  
(Gentiopicroside)  
Cat. No.: HY-N0494

**Bioactivity:** Gentiopicroside, a naturally occurring iridoid glycoside, inhibits P450 activity, with an IC\textsubscript{50} of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has antanti-inflammatory and antioxidative effects.

**Purity:** 98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 10 mg, 25 mg, 50 mg, 100 mg

---

**Ginsenoside C-K**  
(Ginsenoside K; Ginsenoside compound K)  
Cat. No.: HY-N0904

**Bioactivity:** Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC\textsubscript{50} values of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

**Purity:** 98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg

---

**Ginsenoside F1**  
(20(S)-Ginsenoside F1)  
Cat. No.: HY-N0598

**Bioactivity:** Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.

**Purity:** 99.05%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

---

**Ginsenoside Rd**  
(Gypenoside VIII)  
Cat. No.: HY-N0043

**Bioactivity:** Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC\textsubscript{50} of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca\textsuperscript{2+} influx. Ginsenoside...

**Purity:** 98.0%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg

---

**Isavuconazole**  
(BAL-4815; RO-0094815)  
Cat. No.: HY-14273

**Bioactivity:** Isavuconazole is a moderate inhibitor of CYP3A4 and a water-soluble triazole with broad-spectrum antifungal activity.

**Purity:** 99.99%  
**Clinical Data:** Phase 3  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

---

**Isosilybin**  
(Isosilybinin)  
Cat. No.: HY-N0779

**Bioactivity:** Isosilybin (Isosilybinin) is a flavonoid from milk thistle, inhibits CYP3A4 induction with an IC\textsubscript{50} of 74 μM.

**Purity:** 98.97%  
**Clinical Data:** No Development Reported  
**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg

---

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoconazole (R-41400; (+)-Ketoconazol)</td>
<td>99.67%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 100 mg, 1 g, 5 g</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCH-1 antagonist 1</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCH-1 antagonist 1 is a potent melanin concentrating hormone (MCH-1) antagonist with a Kᵢ of 2.6 nM. MCH-1 antagonist 1 also inhibits CYP3A4 with an IC₅₀ of 10 μM.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memantine hydrochloride (D-145 (hydrochloride))</td>
<td>98.0%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 1 g, 5 g</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memantine (hydrochloride) (D-145 (hydrochloride)), an amantadine derivative with low to moderate-affinity for NMDA receptors, inhibit CYP2B6 and CYP2D6 with Kᵢ of 0.51 nM and 94.9 μM, respectively.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methysticin (DL-Methysticin; (+)-Methystici)</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methysticin is a major kavalactone in kava extract to induce CYP1A1.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methoxsalen (8-Methoxypsoralen; Xanthotoxin; 8-MOP)</td>
<td>99.98%</td>
<td>Launched</td>
<td>10mM x 1mL in Water, 500 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metyrapone (Su-4885)</td>
<td>99.83%</td>
<td>Launched</td>
<td>10mM x 1mL in Water, 500 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metyrapone is an inhibitor of cytochrome P450-mediated ω/ω-1 hydroxylase activity and CYP11B1. Target: CYP11B1 Metyrapone is a drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing’s syndrome (hypercortisolism). Metyrapone blocks cortisol synthesis by...</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-Nornuciferine</td>
<td>99.95%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-Nornuciferine is an aporphine alkaloid in lotus leaf that significantly inhibits CYP2D6 with IC₅₀ and Kᵢ of 3.76 and 2.34 μM, respectively.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naringin (Naringoside)</td>
<td>99.50%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 200 mg, 10 g</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and ant apoptotic activities.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ODM-204</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 100 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC₅₀ of 80 nM and 22 nM, respectively.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olivetol</td>
<td>98.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 100 mg</td>
</tr>
<tr>
<td>Bioactivity:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB₁ and CB₂ [3]. Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀ of 1...</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pradefovir mesylate  
(Remofovir mesylate)  
Cat. No.: HY-112690A

Bioactivity: Pradefovir mesylate is a good substrate for liver CYP3A4. Pradefovir is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human liver microsomes with a $K_{m}$ of 60 μM.

Purity: 99.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg

Proadifen hydrochloride  
(SKF-525A; U-5446; RP-5171)  
Cat. No.: HY-B1311

Bioactivity: Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).

Purity: 99.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 250 mg, 500 mg

Pyributicarb  
(TSH-888)  
Cat. No.: HY-111202

Bioactivity: Pyributicarb, a carbamate-type herbicide, is a potent activator of both CYP3A4 gene and human pregnane X receptor (hPXR).

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg

Revexepride  
Cat. No.: HY-U00373

Bioactivity: Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

RG-12525  
(NID 525)  
Cat. No.: HY-101676

Bioactivity: RG-12525 is a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTD4-, LTD4- and LTE4-induced guinea pig parenchymal strips contractions, with IC50's of 2.6 nM, 2.5 nM and 7 nM, respectively. RG-12525 is also a peroxisome...

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Salvianolic acid C  
Cat. No.: HY-N0319

Bioactivity: Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P4502J2 (CYP2J2), with $K_{i}$s of 4.82 μM and 5.75 μM for CYP2CB and CYP2J2, respectively.  

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg

Schisandrin A  
(Schizandrin-A; Wuweizisu-A; Deoxyschizandrin)  
Cat. No.: HY-N0693

Bioactivity: Schisandrin A inhibits CYP3A activity with an IC50 of 6.60 μM and $K_{i}$ of 5.83 μM, respectively.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg

Seviteronel  
(VT-464)  
Cat. No.: HY-15996

Bioactivity: Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase ICso=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.

Purity: 99.11%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Seviteronel racemate  
(VT-464 (racemate))  
Cat. No.: HY-15996B

Bioactivity: Seviteronel (VT-464) racemate is the racemate form of Seviteronel (VT-464), which is a potent CYP17 lyase inhibitor(h-Lyase ICso=69 nM)inhibition.

Purity: 98.11%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Stiripentol  
(BCX2600)  
Cat. No.: HY-103392

Bioactivity: Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with $K_{i}$s of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 ...
Talarozole (R115866) Cat. No.: HY-14531

Bioactivity: Talarozole is a potent inhibitor of both CYP26A1 and CYP26B1, with IC_{50} of 5.4 and 0.46 nM, respectively.

Purity: 99.54%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Talarozole R enantiomer ((R)-Talarozole) Cat. No.: HY-14802

Bioactivity: Talarozole R enantiomer is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis and acne.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tebuconazole Cat. No.: HY-80852

Bioactivity: Tebuconazole is an agricultural azole fungicide which can also inhibit CYP51 with IC_{50} of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 200 mg, 1 g

Tetrahydrocurcumin (HZIV 81-2) Cat. No.: HY-N0893

Bioactivity: Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit CYP2C9 and CYP3A4.

Purity: 95.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg

TMS ((E)-2,3',4,5'-tetramethoxystilbene) Cat. No.: HY-19340

Bioactivity: TMS is a selective inhibitor of CYP1B1 activity.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Veledimex (INXN-1001; RG-115932) Cat. No.: HY-16785

Bioactivity: Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.

Purity: 99.09%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Veledimex racemate (RG-115932 racemate; INXN-1001 racemate) Cat. No.: HY-16785A

Bioactivity: Veledimex racemate is the racemate of veledimex. Veledimex is an orally available, small-molecule activator ligand for the RheoSwitch Therapeutic System.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Veledimex S enantiomer (INXN-1001 S enantiomer; RG-115932 S enantiomer) Cat. No.: HY-16785B

Bioactivity: Veledimex S enantiomer is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.

Purity: 99.52%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg